Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer

被引:20
|
作者
Tanner, Edward J. [1 ]
Long, Kara C. [1 ]
Zhou, Qin [2 ]
Brightwell, Rachel M. [1 ]
Gardner, Ginger J. [1 ]
Abu-Rustum, Nadeem R. [1 ]
Leitao, Mario M., Jr. [1 ]
Sonoda, Yukio [1 ]
Barakat, Richard R. [1 ]
Iasonos, Alexia [2 ]
Chi, Dennis S. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10065 USA
关键词
Cytoreductive surgery; Advanced ovarian cancer; Operative start time; QUALITY-IMPROVEMENT; SLEEP-DEPRIVATION; SURGERY; SURVIVAL; MORBIDITY; PERFORMANCE; CARCINOMA; DISEASE; PART;
D O I
10.1016/j.ygyno.2012.04.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. To evaluate the impact of operative start time (OST) on surgical outcomes in patients with advanced ovarian cancer. Methods. All stage IIIB-IV serous ovarian cancer patients who underwent primary surgery at our institution from 1/01 to 1/10 were identified. Fourteen factors were evaluated for an association with surgical outcomes including OST and OR tumor index (1 point each for carcinomatosis and/or bulky [>= 1 cm] upper abdominal disease). Univariate logistic regression considering within-surgeon clustering was performed for cytoreduction to <= 1 cm versus > 1 cm residual disease. In patients with <= 1 cm residual disease, univariate logistic regression considering within-surgeon clustering was performed for 1-10 mm residual disease versus complete gross resection (CGR, 0 mm residual). A multivariate logistic model was developed based on univariate analysis results in the <= 1 cm residual disease cohort. Results. Of 422 patients, residual disease was: 0 mm, 144 (34.1%); 1-10 mm, 175 (41.5%); > 10 mm, 103 (23.3%). OST was not associated with cytoreduction to <= 1 cm residual disease on univariate analysis. In the <= 1 cm residual disease cohort, albumin, CA-125, ascites, ASA score, stage, OR tumor index, and OST were associated with CGR on univariate analysis. Earlier OSTs were associated with increased rates of CGR. On multivariate analysis, CA-125 was independently associated with CGR. OST was associated with CGR in patients with an OR tumor index of 2 but not an OR tumor index < 2. Conclusions. OST was not associated with cytoreduction to <= 1 cm residual disease in patients with advanced serous ovarian cancer. In the cohort of patients with <= 1 cm residual disease, later OSTs were associated with reduced rates of CGR in patients with greater tumor burden. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 50 条
  • [41] IMPACT OF INCORPORATION OF EXTENSIVE SURGICAL PROCEDURES ON SURGICAL OUTCOMES IN ADVANCED OVARIAN CANCER
    Cardenas Puiggros, L.
    Taltavull Pons, A.
    Fina Planas, C.
    Barretina Ginesta, M. P.
    Sala Hernandez, E.
    Alvarez Castano, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A448 - A449
  • [42] HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2025, 22 (01) : 2 - 2
  • [43] When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?
    Martinek, Igor E.
    Kehoe, Sean
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [44] THE CAVITATIONAL ULTRASONIC SURGICAL ASPIRATOR FOR CYTOREDUCTION IN ADVANCED OVARIAN-CANCER
    ROSE, PG
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) : 843 - 846
  • [45] Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
    Bristow, Robert E.
    Eisenhauer, Eric L.
    Santillan, Antonio
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (02) : 480 - 490
  • [46] Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer
    Desale, M. G.
    Tanner, E. J., III
    Sinno, A. K.
    Angarita, A. Africano
    Fader, A. N.
    Stone, R. L.
    Levinson, K. L.
    Bristow, R. E.
    Roche, K. Long
    GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 61 - 64
  • [47] Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer
    Gillette-Cloven, N
    Burger, RA
    Monk, BJ
    McMeekin, DS
    Vasilev, S
    DiSaia, PJ
    Kohler, MF
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2001, 193 (06) : 626 - 632
  • [48] Nomogram for Suboptimal Cytoreduction at Primary Surgery for Advanced Stage Ovarian Cancer
    Gerestein, Cornelis G.
    Eijkemans, Marinus J.
    Bakker, Jeanette
    Elgersma, Otto E.
    Van der Burg, Maria E. L.
    Kooi, Geertruida S.
    Burger, Curt W.
    ANTICANCER RESEARCH, 2011, 31 (11) : 4043 - 4049
  • [49] Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction
    Grabowski, J. P.
    Mardas, M.
    Markowska, A.
    Markowska, J.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (03) : 274 - 277
  • [50] Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer
    Kolev, Valentin
    Mironov, Svetlana
    Mironov, Oleg
    Ishill, Nicole
    Moskowitz, Chaya S.
    Gardner, Ginger J.
    Levine, Douglas A.
    Hricak, Hedvig
    Barakat, Richard R.
    Chi, Dennis S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (06) : 979 - 984